Adenovirus Infections in Hematologic Malignancy and Hematopoietic Cell Transplant Recipients: Epidemiology, Diagnosis, and Management
Infection & Chemotherapy · 2026 · 58 (2) · 137
DOI: 10.3947/ic.2026.0033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection & Chemotherapy, 2026. Verfasst von Scott Schoninger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institute of Health/National Cancer Institute.
Abstract (Originalsprache)
Human adenovirus (HAdV) infection represents a significant cause of morbidity and mortality in patients with hematologic malignancies, particularly following allogeneic hematopoietic stem cell transplant. Clinical manifestations range from asymptomatic DNAemia to pneumonitis, enterocolitis, hepatitis, hemorrhagic cystitis, myocarditis, and central nervous system disease. Advances in molecular diagnostics, including quantitative polymerase chain reaction, have enabled earlier detection and surveillance, yet interpretation remains challenging given the absence of standardized viral load thresholds and international quantitative standards. Reported incidence varies by age, transplant type, geographic regions, and surveillance strategy, with pediatric recipients demonstrating higher infection rates, while mortality among patients with DNAemia or disseminated disease remains substantial. Risk factors include T-cell depletion, cord blood transplant, severe graft-versus-host disease, high-dose corticosteroid exposure, and delayed immune reconstitution. Management relies primarily on immune recovery and reduction of immunosuppression when feasible. Intravenous cidofovir remains the most widely used antiviral despite nephrotoxicity, while intravenous brincidofovir represents a potentially promising emerging approach. The impact of contemporary transplant approaches, including post-transplant cyclophosphamide and novel cellular therapies, on HAdV epidemiology requires further study. This review summarizes contemporary epidemiology, definitions, diagnostic strategies, and evolving therapeutic options for HAdV infection in patients with hematologic malignancies, highlighting ongoing challenges.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Diseases and Allergy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Division of Infectious Diseases, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
- Weill Cornell Medical College, New York, NY, USA. leey3@mskcc.org.
ORCID-Profile: Scott Schoninger, Hyeon Mu Jang, Yeon Joo Lee
Förderung
- NCI NIH HHS
- National Institute of Health/National Cancer Institute
Zitieren
APA
Schoninger, S., Jang, H. M., & Lee, Y. J. (2026). Adenovirus Infections in Hematologic Malignancy and Hematopoietic Cell Transplant Recipients: Epidemiology, Diagnosis, and Management. Infection & Chemotherapy, 58(2), 137. https://doi.org/10.3947/ic.2026.0033
Vancouver
Schoninger S, Jang HM, Lee YJ. Adenovirus Infections in Hematologic Malignancy and Hematopoietic Cell Transplant Recipients: Epidemiology, Diagnosis, and Management. Infection & Chemotherapy. 2026;58(2):137. doi:10.3947/ic.2026.0033
BibTeX
@article{Schoninger2026,
author = {Schoninger, Scott and Jang, Hyeon Mu and Lee, Yeon Joo},
title = {Adenovirus Infections in Hematologic Malignancy and Hematopoietic Cell Transplant Recipients: Epidemiology, Diagnosis, and Management},
journal = {Infection & Chemotherapy},
year = {2026},
volume = {58},
number = {2},
pages = {137},
doi = {10.3947/ic.2026.0033}
}
EUVIMED